New scan could match patients to best drug after treatment fails
NCT ID NCT06595563
Summary
This study is for people with advanced HER2-positive breast cancer whose disease has worsened on a specific drug (T-DXd). It tests if a special imaging scan (HER2-PET/CT) can predict who might benefit from switching to another targeted drug (T-DM1). Patients get the scan and a biopsy; those with a 'positive' scan result receive T-DM1, while those with a 'negative' result receive their doctor's choice of treatment. The goal is to see if the scan can help choose the right next treatment more accurately.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Jules Bordet
RECRUITINGAnderlecht, Brussels Capital, 1070, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.